Vir Biotechnology
232 hedge funds and large institutions have $2.06B invested in Vir Biotechnology in 2023 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 83 increasing their positions, 76 reducing their positions, and 25 closing their positions.
58% more call options, than puts
Call options by funds: $11M | Put options by funds: $6.98M
44% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 25
38% more capital inflows, than outflows
Capital inflows: $228M | Capital outflows: $165M
4% more funds holding
Funds holding: 223 → 232 (+9)
1.62% more ownership
Funds ownership: 64.63% → 66.25% (+1.6%)
9% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 76
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$43M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$20.2M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$16.8M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$15.4M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB Investment Advisers (UK)
London,
United Kingdom
|
-$49.6M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$28.1M |
| 3 |
Morgan Stanley
New York
|
-$14.8M |
| 4 |
Capital Fund Management (CFM)
Paris,
France
|
-$5.76M |
| 5 |
Goldman Sachs
New York
|
-$5.66M |
VIR Hedge Fund Activity: Q1 2023 in Review
232 of the 6,287 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q1 2023, worth a combined $2.06B — down 5.4% from $2.18B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new VIR positions and 25 closed out — a net gain of 11 holders — while 83 added to existing stakes and 76 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $43M. The largest seller was SB Investment Advisers (UK), cutting an estimated $49.6M.
- 232 institutional investors held Vir Biotechnology (VIR) as of Q1 2023, up from 223 in Q4 2022.
- Funds reported $2.06B of Vir Biotechnology stock for Q1 2023, down 5.4% quarter-over-quarter.
- 36 funds opened new Vir Biotechnology positions in Q1 2023 and 25 closed out, a net change of +11 holders.
- The largest Vir Biotechnology buyer in Q1 2023 was Point72 Asset Management, an estimated $43M added.
- The largest Vir Biotechnology seller in Q1 2023 was SB Investment Advisers (UK), an estimated $49.6M sold.
Based on aggregated 13F filings for Q1 2023.